Results 51 to 60 of about 4,008,604 (402)

Role of Interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression [PDF]

, 2010
Background: The use of TNF inhibitors has been a major progress in the treatment of chronic inflammation. However, not all patients respond. In addition, response will be often lost when treatment is stopped. These clinical aspects indicate that other
A Maitra, Anne Tournadre, B Bennett, B Gao, D Alessi, D Borderie, D Borderie, D Eizirik, D Lacey, D Toy, David Boyle, Derya Unutmaz, E Bettelli, E Lubberts, E Nadav, Erik Lubberts, F Arnett, G Firestein, G Page, Gaelle Gonzales, Gary S. Firestein, H Hsu, H Nakamura, J Anolik, J Dufour, J Lee, K Aupperle, L Harrington, M Kaneko, M Kikkert, M Koenders, M Leech, M Toh, M Toh, M Toh, M Toh, Marije I. Koenders, MI Koenders, Myew-Ling Toh, N Yagishita, P Miossec, Pierre Miossec, Q Chen, R Swandner, S Chang, S Cohen, S Hwang, S Hymowitz, S Oyadomari, S Yamasaki, S Zrioual, S Zrioual, T Amano, T Amano, T Gotoh, Wim B. van den Berg, Y Qian, Yuan Zhou, Z You   +58 more
core   +6 more sources

The role of interleukin-17 in asthma: a protective response?

ERJ Open Research, 2020
While there now exist effective treatments for type 2 high, eosinophilic asthma, there are no specific therapies for 40–50% of people with asthma with other phenotypes, which result from poorly understood underlying pathological mechanisms.
G. Hynes, T. Hinks
semanticscholar   +1 more source

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis [PDF]

World Journal of Hepatology, 6(10):759-765, 2014, 2014
AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\alpha$ (Peg-INF-$\alpha$) based triple-therapy.
arxiv   +1 more source

Influence of interleukin 17 A and 17 F polymorphisms in keratoconus

Molecular Biology Reports, 2021
Until a few years ago, keratoconus was defined as a noninflammatory degenerative disease. However, recent studies have shown that the altered balance between inflammatory cytokines, proteases, and protease inhibitors, as well as free radicals and oxidants, have a crucial role in the pathogenesis of this disease.
Isabela Bronchtein Gomes, Christiane Maria Ayo, Alessandro Garcia Lopes, Laurie Sayuri Kumano, Geraldo Magela de Faria Junior, Gildásio Castello de Almeida, Lilian Castiglioni, Luiz Carlos de Mattos, Cinara Cássia Brandão   +8 more
openaire   +4 more sources

Interleukin‐17 and its target genes: mechanisms of interleukin‐17 function in disease [PDF]

Immunology, 2010
SummaryInterleukin‐17 (IL‐17) has emerged as a central player in the mammalian immune system. Although this cytokine exerts a host‐defensive role in many infectious diseases, it promotes inflammatory pathology in autoimmunity and other settings. A myriad of studies have focused on how IL‐17‐producing cells are generated.
Sarah L. Gaffen, Sarah L. Gaffen, Reiko M. Onishi   +2 more
openaire   +3 more sources

Serum interleukin-17 (IL-17) in chronic periodontitis patients

Padjadjaran Journal of Dentistry, 2017
Introduction: Explorations into the periodontal medicine relationship have discovered interleukin-17 (IL-17) cytokine as one of the pro-inflammatory mediators that play a crucial role in the initiation and progression of the chronic periodontal disease ...
Erry Mochamad Arief, Marina binti Mubin, Siti Lailatul Akmar Zainuddin, Nurul Asma Abdullah, Basaruddin Ahmad   +4 more
doaj   +1 more source

The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases

Current Issues in Molecular Biology, 2022
IL-17 inhibitors (IL-17i) are medicines used to treat dermatological and rheumatic diseases They belong to a class of medicines called biological disease-modifying anti-rheumatic drugs (bDMARDs).
Laura Țiburcă, Marius Bembea, Dana Carmen Zaha, Alexandru Daniel Jurca, Cosmin Mihai Vesa, Ioana Adela Rațiu, Claudia Maria Jurca   +6 more
doaj   +1 more source

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

Acta Dermato-Venereologica, 2020
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice.
C. Phan, N. Bénéton, J. Delaunay, Z. Reguiai, C. Boulard, A. Fougerousse, E. Cinotti, M. Romanelli, L. MÉRY-BOSSARD, D. Thomas-Beaulieu, J. Parier, F. Maccari, J. Perrot, M. Ruer-Mulard, M. Bastien, E. Bégon, M. Samimi, C. Jacobzone, N. Quiles-Tsimaratos, V. Descamps, M. Steff, P. Bilan, A. Vermersch-Langlin, M. Kemula, E. Amazan, I. Kupfer-Bessaguet, A. Cottencin, F. Prignano, Bulai Livideanu, J. Gottlieb, A. Beauchet, E. Mahé   +31 more
semanticscholar   +1 more source

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma

Advanced Biomedical Research, 2014
Asthma is a reversible airway obstruction that is characterized by constriction of airway smooth muscle, hyper secretion of mucus, edema and airway hyper responsiveness (AHR), mucus secretion and thickening of the basement membrane underlying the airway ...
Rahim Farahani, Roya Sherkat, Mazdak Ganjalikhani Hakemi, Nahid Eskandari, Reza Yazdani   +4 more
doaj   +1 more source

Is interleukin-17 implicated in early knee osteoarthritis pathogenesis as in rheumatoid arthritis?

Egyptian Rheumatology and Rehabilitation, 2022
Background Interleukin-17 (IL-17) is a cytokine that promotes activation of multiple catabolic pathways resulting in cartilage and tissue damage. It has features making it increasingly attractive as a biological marker, especially in rheumatoid arthritis
Hoda M. Abdel-Naby, Sarah S. El-Tawab, Mohamed M. Rizk, Nesrin A. Aboeladl   +3 more
doaj   +1 more source